BONESUPPORT commenced trading on Nasdaq Stockholm following completion of its IPO, for which the final price was set at SEK 29/share (~US $3.31/share). Final proceeds after issue costs will be SEK 461MM (~$53.0MM).
BONESUPPORT markets CERAMENT injectable, drug-eluting bioceramic bone graft substitutes to treat bone voids. Funds will support U.S. and EU sales, collection of clinical data, product development, etc. In mid-2Q17, the company enrolled the first patient in the pivotal Investigational Device Exemption FORTIFY trial, “A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures,” that is key to the company’s pursuit of U.S. approval for the product.
Sources: BONESUPPORT AB; ORTHOWORLD Inc.
BONESUPPORT commenced trading on Nasdaq Stockholm following completion of its IPO, for which the final price was set at SEK 29/share (~US $3.31/share). Final proceeds after issue costs will be SEK 461MM (~$53.0MM).
BONESUPPORT markets CERAMENT injectable, drug-eluting bioceramic bone graft substitutes to treat bone voids. Funds will...
BONESUPPORT commenced trading on Nasdaq Stockholm following completion of its IPO, for which the final price was set at SEK 29/share (~US $3.31/share). Final proceeds after issue costs will be SEK 461MM (~$53.0MM).
BONESUPPORT markets CERAMENT injectable, drug-eluting bioceramic bone graft substitutes to treat bone voids. Funds will support U.S. and EU sales, collection of clinical data, product development, etc. In mid-2Q17, the company enrolled the first patient in the pivotal Investigational Device Exemption FORTIFY trial, “A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures,” that is key to the company’s pursuit of U.S. approval for the product.
Sources: BONESUPPORT AB; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.